The long-term survival of plasma cells is entirely dependent on signals derived from their environment. These extrinsic factors presumably induce and sustain the expression of antiapoptotic proteins of the Bcl-2 family. It is uncertain whether there is specificity among Bcl-2 family members in the survival of plasma cells and whether their expression is linked to specific extrinsic factors. We found here that deletion of the gene encoding the antiapoptotic protein Mcl-1 in plasma cells resulted in rapid depletion of this population in vivo. Furthermore, we found that the receptor BCMA was needed to establish high expression of Mcl-1 in bone marrow but not spleen plasma cells and that establishing this survival pathway preceded the component of plasma cell differentiation that depends on the transcriptional repressor Blimp-1. Our results identify a critical role for Mcl-1 in the maintenance of plasma cells.
High-affinity neutralizing antibodies protect the body against foreign organisms and their toxic products. These antigen-specific antibodies are secreted by plasma cells, which arise by differentiation from activated B lymphocytes. The completion of plasma cell differentiation, rather than its initiation, depends on the expression of the transcriptional repressor Blimp-1 (refs. 1-3); indeed, subsets of plasma cells can be identified on the basis of high and intermediate Blimp-1 expression, as has been shown through the use of a green fluorescent protein (GFP) reporter 4 . Most long-lived plasma cells are produced in response to protein-containing antigens in transient structures called 'germinal centers' , in which B lymphocytes undergo extensive proliferation and maturation. Throughout rounds of proliferation, a fraction of B cells undergo differentiation and leave the germinal centers as either plasma cells or memory B cells. Both of these cell types have the capacity for longevity; plasma cells migrate to specialized niches 5 , whereas memory B cells recirculate between lymphoid organs 6, 7 . Germinal center−derived plasma cells seem to persist mainly in the bone marrow. The emigration of plasma cells from secondary lymphoid organs is mediated by the induction of sphingosine 1-phosphate receptor type 1 in plasma cells 8 , whereas expression of the chemokine receptor CXCR4 promotes the recruitment of plasma cells into bone marrow niches and contributes to the positioning of plasma cells near bone marrow stromal cells expressing the chemokine CXCL12 (ref. 9) . Most plasma cells in the bone marrow have a mature plasma cell phenotype, as indicated by low expression of major histocompatibility complex class II and the B cell-associated markers B220 and CD19 but high Blimp-1 expression 10 . In addition to giving rise to germinal center−derived plasma cells, activated B cells can give rise to plasma cells in extrafollicular foci in the spleen 10 . These antibody-secreting cells are generated soon after immunization or infection, have lower expression of Blimp-1 than do long-lived plasma cells in the spleen and bone marrow 4 and are generally short-lived, dying by apoptosis in situ 11 .
In niches that promote the survival of plasma cells, plasma cells receive signals from local stromal cells that are crucial for their longterm survival. Proposed mediators of survival include ligands for the receptor BCMA (APRIL (a proliferation-inducing ligand) and BAFF (a B cell-activation factor)) 12, 13 , the cytokines interleukin 4 (IL-4), IL-5 and IL-6, tumor-necrosis factor 14, 15 , ligands of the activation and memory marker CD44, costimulatory molecules CD80 and CD86 (ref. 16 ) and CXCL12 (ref. 17) . Many of these promote the expression of antiapoptotic proteins of the Bcl-2 family 12, [18] [19] [20] [21] , but the in vivo expression of Bcl-2 family members and their relevance, individually and collectively, in the survival of long-lived plasma cells in the whole animal remain to be elucidated.
Treatment of mice with the Bcl-2 homology domain mimetic ABT-737, a compound that binds in Biacore studies with high affinity to Bcl-2 and the Bcl-2 family members Bcl-w and Bcl-x L (but not to Mcl-1t or A1), inhibits the appearance of plasma cells in the bone marrow during the treatment period but does not affect the maintenance of pre-existing plasma cells 22 . Notably, in contrast to those affinity measurements made with Biacore, other studies have shown that Bcl-2 (but not Bcl-x L or Bcl-w) is the main target of ABT-737 in the lymphoid lineage in vivo 23 . Together those observations suggest that newly formed plasma cells depend at least transiently on Bcl-2 expression but that such dependence on Bcl-2 may be lost in long-lived plasma cells. Additionally, Cre recombinase-mediated deletion of the gene encoding Bcl-X L (Bcl2l1; called 'Bclx' here) in A r t i c l e s B cells expressing activation-induced cytidine deaminase leads to a significant decrease in the abundance of of antigen-specific plasma cells in the bone marrow at 14 d after immunization, but not after 21 d (ref. 24) . This suggests that Bcl-x L may also support the survival of recently generated plasma cells. In contrast to the described roles of Bcl-2 and Bcl-x L in newly formed plasma cells, it is unknown which survival molecule(s) mediate(s) the survival of long-lived plasma cells in their niche.
Although plasma cells have a crucial role in maintaining lifelong humoral immunity, and the relatively long life span of plasma cells is essential for this function, the underlying molecular mechanism of their long-term survival in vivo is unknown. To address this issue, we examined the expression of prosurvival molecules of the Bcl-2 family and examined their function in vivo. We identified Mcl-1 as being essential for the survival of plasma cells and found that signaling through the receptor BCMA facilitated high expression of Mcl-1 in bone marrow plasma cells. This insight may aid the development of new therapeutic strategies for the manipulation of long-lived plasma cells in autoimmune diseases and plasma cell−derived cancers, such as multiple myeloma.
RESULTS

Expression of plasma cell prosurvival Bcl-2 proteins
We examined the expression of various members of the Bcl-2 family in plasma cells isolated from the spleen and bone marrow of adult mice, and compared that to their expression in naive and germinal center B cells. Transcripts encoding Bcl-2 (Bcl2), Bcl-w (Bcl2l2) and Mcl-1 (Mcl1) were all detectable in plasma cells (Fig. 1a) , whereas, as reported 25 , expression of the Bcl-2 family member A1 (encoded by Bcl2a1a) was strongly repressed (Fig. 1a) . Expression of prosurvival Bcl-2 family members in the Blimp-1 hi and Blimp-1 int plasma cell subsets, identified through the use of Blimp-1-GFP reporter mice (in which sequence encoding GFP is expressed from the gene encoding Blimp-1 (Prdm1 GFP ) 4 ), was essentially unchanged from that in the unseparated plasma cell population (Supplementary Fig. 1 ). The greater abundance of both Bcl2 mRNA and Mcl1 mRNA in plasma cells than in naive B cells was reflected in the greater abundance of their proteins, as determined by immunoblot analysis of extracts of plasma cells isolated from spleen and bone marrow ( Fig. 1b and  Supplementary Fig. 2 ).
Published experiments with ABT-737 have ruled out a substantial role for Bcl-2 in the survival of existing plasma cells 22, 23 . However, the low but detectable expression of Bcl2l1 (Fig. 1a) could have supported survival of long-lived plasma cells. Therefore, we examined the effect of conditional deletion of Bcl2l1 in existing plasma cells in vivo. For this, we reconstituted lethally irradiated Ly5.1 + recipient mice with a mixture of µMT bone marrow (which can generate all hematopoietic cells except B cells) and bone marrow in which all B cells carried the Rosa26-Cre ERT2 allele (and thus expressed a tamoxifen-sensitive variant of Cre recombinase from the ubiquitous Rosa26 locus; called 'Cre ERT2 ' here) and were either Bcl2l1 +/+ or had loxP-flanked Bcl2l1 alleles (Bcl2l1 fl/fl ). We immunized those bone marrow chimeras with nitrophenyl coupled to keyhole limpet hemocyanin (NP-KLH) in the adjuvant alum and treated them with two doses of tamoxifen (by oral gavage) 14 d later. To measure Bcl2l1 expression after tamoxifen treatment, we isolated plasma cells from the bone marrow 2 d after the start of treatment and detected a lower abundance of Bcl2l1 transcripts (Supplementary Fig. 3a) . Because Bcl-x L protein is expected showing a considerably fewer antigen-specific plasma cells (17% as many) 12 and total plasma cells (less than 50% as many) 27 in the bone marrow, but not the spleen, of Bcma −/− mice than in that of wildtype mice. Together these data showed that higher expression of the prosurvival protein Mcl-1 was influenced by expression of BCMA on plasma cells residing in the bone marrow compartment.
Bcma induction is Blimp-1 independent BCMA, a member of the tumor-necrosis factor receptor family, has high expression in mouse and human plasma cells but is absent from naive B cells, germinal center B cells and memory B cells 13, 28 . We sought to measure BCMA relative to the changes in Blimp-1 expression that occur during the differentiation of activated B cells into plasma cells. As functional antibodies to mouse BCMA are lacking at present, we assessed the expression of Bcma mRNA by quantitative real-time PCR. We detected large amounts of Bcma mRNA in Blimp-1 int plasma blasts and Blimp-1 hi plasma cells in the spleen and bone marrow of Blimp-1-GFP reporter mice 3 (Prdm1 GFP/+ ; Fig. 3a) .
As we expected, we found that Bcma mRNA was absent from naive B cells and germinal center B cells in these mice (Fig. 3a) . These results indicated that induction of BCMA was part of a transcriptional program specifically induced after plasma cell differentiation. However, when we cultured
All genes ( to be relatively stable, we assessed the consequences of the deletion of Bcl2l1 on plasma cell frequency 4 d after the start of tamoxifen treatment, which was 18 d after immunization. We observed no significant difference between Bcl2l1 +/+ Cre ERT2 and Bcl2l1 fl/fl Cre ERT2 mice in percentage or absolute number of either total or antigen-specific plasma cells in the spleen or bone marrow (P > 0.05; Supplementary  Fig. 3b,c) . These data indicated that expression of Bcl-x L was not crucial for the survival of existing plasma cells.
BCMA regulates bone marrow plasma cell Mcl-1 expression Next we investigated several extracellular factors and signals available in bone marrow niches for their ability to elicit the expression of Bcl-2, Bcl-x L , Bcl-w and Mcl-1 in plasma cells. Ligand-receptor interactions, including IL-6-IL-6 receptor, CD80-and/or CD86-CD28 and APRIL-BCMA can promote the survival of plasma cells in vivo 26 . We analyzed the frequency of plasma cells in mice deficient in the gene encoding IL-6 (Il6 −/− ) or BCMA (Tnfrsf17 −/− ; called 'Bcma −/− ' here) or deficient in the genes encoding CD80 and CD86 (Cd80 −/− Cd86 −/− ).
As we expected, we found that the lack of any of these three pathways in mice led to fewer plasma cells than those in wild-type mice; this difference was significant in the bone marrow compartment but not in the spleen (Fig. 2a,b) .
To determine whether those three distinct pathways contributed to the induction of prosurvival members of the Bcl-2 family, we isolated plasma cells from the spleen and bone marrow of control (wildtype), Il6 −/− , Cd80 −/− Cd86 −/− and Bcma −/− mice and measured the mRNA enoding various prosurvival members of the Bcl-2 family. We observed no significant difference among genotypes in such expression in plasma cells isolated from the spleen (Fig. 2c) . However, plasma cells from the bone marrow of Bcma −/− mice showed abnormally lower expression of both Mcl1 mRNA (Fig. 2c) and Mcl-1 protein ( Fig. 2d and Supplementary Fig. 4 ). Although we observed no compensatory upregulation of the expression of other prosurvival members of the Bcl-2 family (Fig. 2c) , we found significantly lower expression of the gene encoding Bim in plasma cells from the bone marrow of Bcma −/− mice ( Supplementary Fig. 5 ). Thus, of the three different mutant mouse strains we examined, Bcma −/− mice had the fewest total bone marrow plasma cells relative to those in wild-type mice (30% as 3 under conditions of plasma cell differentiation, we observed considerable induction of Bcma expression in activated GFP + B cells; that is, B cells with an active Prdm1 locus that were arrested in the earliest stage of plasma cell differentiation 3 (Fig. 3b,c) . This observation indicated that initiation of Bcma transcription was Blimp-1 independent. Moreover, genome-wide microarray analysis showed that Bcma was among the genes most induced in Blimp-1 int plasma blasts in the spleen of Blimp-1-GFP reporter mice, relative to expression in naive B cells (Fig. 3d) . Collectively, these data indicated that initiation of the BCMA-mediated plasma cell survival pathway was independent of the Blimp-1-dependent component of plasma cell differentiation and that it had a role in regulating Mcl-1 expression in plasma cells.
Mcl-1 promotes plasma cell survival in vitro
The higher expression of Mcl-1 in normal plasma cells and the lower Mcl-1 expression and plasma cell numbers in the absence of BCMA indicated that Mcl-1 might be an essential mediator of plasma cell survival. Indeed, plasma cells in the whole mouse are resistant to ABT-737, an apoptosis-inducing antagonist of Bcl-2, Bcl-x L and Bcl-w, which suggests that these three prosurvival proteins are dispensable for the survival of plasma cells 22 . To examine the requirement for Mcl-1 in the survival of plasma cells, we investigated the effect of conditional deletion of Mcl1 in plasma cells. We generated Mcl1 fl/fl Cre ERT2 mice, in which, after Cre-mediated deletion of Mcl1, human CD4 was expressed on the cell surface under the control of Mcl1 regulatory elements 24, 29 . Surface expression of human CD4 was therefore a reporter of Mcl1 deletion and an indicator of Mcl1 transcription. First, we used human CD4 expression as an indicator of Mcl1 transcription. We cultured B cells from the spleen of Mcl1 fl/+ Cre ERT2 mice under plasma cell−differentiating conditions 30 . We added the BCMA ligand APRIL to the culture medium on day 5 and induced tamoxifen-mediated deletion of the loxP-flanked Mcl1 allele 20 h before analysis on day 6 or 7 of culture. APRILmediated signaling resulted in a significant increase in the expression of human CD4 on plasma blasts over the 20-hour time period after tamoxifen addition (Fig. 4a,b) . That result established a connection between APRIL and the induced transcription of Mcl1. Fig. 6 ). The absolute number of plasma blasts after treatment was lower on both days 6 and 7 of culture. Cells expressing the plasma cell marker CD138 were affected significantly more by Mcl1 deletion than were undifferentiated B cell blasts on day 7 (Fig. 4c,d) . We concluded from these experiments that plasma blasts had both higher expression of Mcl-1 than that od B cell blasts and greater reliance on Mcl-1 for their survival.
Mcl-1-dependent survival of plasma cells in vivo
Our in vitro experiments suggested that Mcl-1 might be an important mediator of plasma cell survival in vivo. To examine the effect of Mcl1 deletion on existing plasma cells in vivo, we created mice through hematopoietic reconstitution after lethal irradiation such that all B cells carried the Rosa26-Cre ERT2 allele and were Mcl1 +/+ , Mcl1 fl/+ or Mcl1 fl/fl . We immunized reconstituted mice with NP-KLH in alum and subsequently treated the mice with two doses of tamoxifen (by oral gavage) either 4 weeks later (Fig. 5a-d) or 26 weeks later (Fig. 5c) . We analyzed spleen and bone marrow 2 d after the start of tamoxifen administration. Mcl1 was deleted in existing plasma cells residing in these tissues, as judged by the cell-surface expression of human CD4 (Fig. 5a) . The percentage and absolute number of total plasma cells (Fig. 5a,b) and antigenspecific plasma cells (Fig. 5c,d) were significantly lower after deletion of both alleles of Mcl1 than in wild-type mice. This difference was considerably greater than that of naive B cells (either immature or mature) and similar to the difference seen with germinal center B cells 24 (Fig. 5a,b and data not shown) . Deletion of one allele of Mcl1 did not affect the percentage or absolute number of total plasma cells (Fig. 5b) but did lead to fewer NP-specific plasma cells 4 weeks after immunization (Fig. 5c) (Fig. 5e) . Whereas the rate of loss of IgG1 antibody to NP in the first 5 d after tamoxifen treatment matched that expected from the 8-day half-life of serum IgG1 in mice 31 , the titer at the end of the experiment was higher than expected, possibly owing to the incomplete depletion of NPspecific plasma cells (Fig. 5c) . We observed also a decrease in the serum titers of total IgG, IgM and IgA that was temporary in all cases (Fig. 5e) . The magnitude and rate of the decrease reflected the serum half-life of the isotypes in that IgM, with a serum half-life of 2 d (ref. 31) , decreased 80% within 5 d of treatment, whereas IgG, with a half-life of 8 d, decreased 30% (Fig. 5e) . At 28 d after tamoxifen treatment, the final time point of this experiment, we counted plasma cells from spleen and bone marrow by flow cytometry. In contrast to our earlier findings (Fig. 5a) , we observed abundant human CD4-negative Mcl1 fl/fl Cre ERT2 plasma cells (Fig. 5f ), which were probably plasma cells differentiated from B cells that had escaped the inducible deletion of Mcl1. We presumed that these cells accounted for the rebound in concentrations of total IgG, IgM and IgA after treatment with tamoxifen.
To rule out possible effects of the lower abundance of naive B cells on the maintenance of plasma cells, we generated mixed-bone marrow chimeras in which ~50% of the hematopoietic cells were wild-type (Ly5.1 + ) and ~50% were either Mcl1 fl/+ Cre ERT2 or Mcl1 fl/fl Cre ERT2 (Ly5.2 + ). We immunized those mice with NP-KLH in alum as described above and treated them with tamoxifen on days 26 and 27, followed by analysis 1 d later. Control Ly5.1 + B cells and plasma cells were unaffected by the tamoxifen treatment, but the proportion and number of Ly5.2 + human CD4-positive Mcl1 fl/fl Cre ERT2 plasma cells in both the spleen and bone marrow was significantly lower (Fig. 6) . Thus, the requirement for continued expression of Mcl1 in the survival of plasma cells was cell intrinsic. 
DISCUSSION
The lifespan of plasma cells is believed to reach years in mice and decades in humans, and they provide protective antibodies for a lifetime in some cases [32] [33] [34] . To achieve such longevity, plasma cells must locate themselves in specialized niches composed of cells that provide the signals necessary to maintain plasma cell viability 35 . Niches in the bone marrow are the best characterized, but long-lived plasma cells are also present in the red pulp of the spleen and mucosa-associated lymphoid tissues 26 . Bone marrow niches contain monocytes, eosinophils, megakaryocytes, CXCL12 + reticular stromal cells, basophils, osteoclasts and osteoblasts 26 . Collectively, these cells provide attractants, anchoring molecules and survival factors that recruit, retain and then sustain bone marrow plasma cells. Among the sustaining molecules are BAFF and APRIL (members of the tumor-necrosis factor superfamily), the cytokine IL-6, and the coreceptor CD28 ligands CD80 and CD86. Determining how these factors mediate the survival of plasma cells, although crucial for understanding the persistence of immunity, has been hampered by lack of knowledge about what molecular mechanism they activate, individually or combined, in the plasma cell. We reasoned that identifying the survival mechanism of plasma cells should help determine the factor(s) responsible for activating that mechanism and the signaling pathways involved. The data presented here have shown that sustained expression of the Bcl-2 family member Mcl-1 exemplifies how niche-derived survival factors mediate the persistence of plasma cells and have further shown that ligands of BCMA mediate this effect in the bone marrow.
BCMA is important for plasma cell survival in vivo, as immunized mice deficient in Bcma have abnormally low numbers of antigenspecific plasma cells in their bone marrow 12 . APRIL, a ligand for BCMA, is produced by bone marrow−resident eosinophils 36 , basophils 15 and monocytes or macrophages 37 in mice, and by neutrophils 38 in humans, and these cell types promote the survival and accumulation of plasma cells. As with immunized Bcma −/− mice, the bone marrow of APRIL-deficient mice supports considerably fewer antigen-specific plasma blasts and plasma cells than does wild-type bone marrow, albeit after transfer rather than with de novo generation 20 . Our results have confirmed the importance of the APRIL-BCMA axis in plasma cell survival in the bone marrow and indicate that this process requires transcriptional induction of Mcl1. How does this model account for plasma cells present in the bone marrow of Bcma −/− mice, albeit at lower frequency and with lower expression of Mcl-1 than that of wildtype mice? This presumably reflects the expression pattern of genes encoding survival molecules that is due to factors acting in addition to BCMA. This suggests that BCMA is positioned to sustain high Mcl-1 expression. The low Bim expression found in Bcma −/− bone marrow plasma cells, although necessary for survival in this case, could reflect the usual expression of Bim among some newly generated plasma cells. Such plasma cells with intrinsically low Bim expression might be infrequent; this could explain the difficulty in establishing new specificities into the Bcma −/− bone marrow plasma cell population 12 .
Notably, we found that that BCMA deficiency affected bone marrow plasma cells much more than spleen plasma cells in both frequency and expression of genes encoding survival molecules. The Bcma −/− bone marrow plasma cell population reflects survival mediated by signals derived from receptors other than BCMA. Splenic plasma cells were sustained at near normal frequency in BCMA-deficient mice and had normal expression of Mcl-1. Thus, the spleen must contain factors that can substitute for BCMA signaling to induce Mcl-1. Plasma cells in spleen and bone marrow continue to express mRNA encoding the transmembrane activator TACI, albeit at lower amounts than its expression by B cell blasts. TACI binds APRIL and BAFF with different affinities, and these ligands might be present in different amounts and/or configurations in spleen and bone marrow, thereby mediating different outcomes through the same receptor. Alternatively, a ligand-receptor system may be available to plasma cells in the spleen that is not available in bone marrow; this system may be composed of some combination of already defined factors or be previously unknown. Whichever is true, analyzing the signals that mediate high expression of Mcl-1 in the persisting long-lived splenic plasma cell will help resolve these issues. Our data have shown that BCMA-mediated expression of Mcl-1 constitutes a plasma cell-survival pathway that arises independently of the Blimp-1-controlled plasma cell-differentiation pathway. B cells induced to differentiate without Blimp-1 progress to a 'pre-plasmablast' stage at which cells secrete small amounts of immunoglobulin, upregulate the transcription factor XBP-1 and downregulate transcription factor Pax5 (ref. 3) . We propose that these cells represent the earliest stage of plasma cell differentiation, one that is by definition Blimp-1 independent 3 . The findings that induction of BCMA expression occurred independently of Blimp-1, that BCMA is encoded by a plasma cell−specific gene and that BCMA was crucial for the survival of fully differentiated cells at the terminus of this pathway support the proposal that Blimp-1 consolidates and amplifies plasma cell differentiation rather than being the 'master regulator' of the process. Indeed, the term "master regulator" may be better reserved for the factors that trigger immunoglobulin secretion and initiate the plasma cell-survival program, such as the transcription factor IRF4. Upregulation of IRF4 expression precedes the induction of Blimp-1 expression 39 , and both Bcma and Prdm1 have been identified as part of a plasma cell-differentiation program induced by IRF4 (ref. 40) .
Plasma cells accumulate 'preferentially' in specific niches in the bone marrow, and it has been suggested that a wide variety of cell types and ligand-receptor pairs contribute to their longevity 41 . However, loss of many of these ligand-receptor pairs on their own diminishes the survival of plasma cells only marginally in vivo 12, 14, 16, 26, 27 . We therefore postulate that many (perhaps all) of these signaling pathways converge after the transcriptional induction of Mcl1 and that their combined action allows the high expression of Mcl-1 in plasma cells. Here we found that the maintenance of Mcl-1 expression in plasma cells was crucial for their survival, as loss of Mcl1 led to rapid disappearance of this cell population. Moreover, we found that signaling through BCMA promoted transcription of Mcl1 and thus was important for the long-term maintenance of bone marrow plasma cells. Both BCMA 42, 43 and Mcl-1 (ref. 44 ) have high expression in plasma cell−derived cancerous multiple myeloma cells and their expression seems to be correlated with tumor cell persistence. Furthermore, two recent clinical phase 2 trials showed that the APRIL-and BAFF-inhibitor atacicept significantly decreased both the number of plasma cells and the amount of immunoglobulins in rheumatoid arthritis patients 45, 46 . This highlights the potential clinical importance of interfering with the survival pathways that promote Mcl-1 expression in plasma cells.
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Methods and any associated references are available in the online version of the paper.
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